



**GMMM** Interface Prescribing  
Subgroup



**Agenda**

**14<sup>th</sup> May 2015, 1pm-3pm**

**HMR CCG**

**Room 410, Number One Riverside, Smith St. Rochdale OL16 1XU**

[Declarations of Interest](#) (new declarations only)

Apologies: Lesley Smith, Robert Hallworth

	<b>ENC</b>
<b>1) Draft Minutes of 9<sup>th</sup> April 2015</b>	Item 1
<b>2) Matters Arising</b> <ul style="list-style-type: none"> <li>a) RAG List Recommendations LMWH – now GMMM approved</li> <li>b) RAG List Recommendations from February meeting – now GMMM approved</li> <li>c) RAG List Recommendations from March meeting (Drugs for alcohol dependence, Chapter 3 and 13) – comments received</li> <li>d) RAG List Recommendations from April meeting (Chapter 1 &amp; 8) – currently out for comment</li> <li>e) Ethinylestradiol for pubertal induction</li> <li>f) Ciclosporin for use in childhood nephrotic syndrome</li> </ul>	Item 2c Item 2e
<b>3) RAG list review</b> – full review of RAG list now complete	Item 3
<b>4) Drugs requiring a review of RAG status</b> <ul style="list-style-type: none"> <li>• Midodrine</li> <li>• Modafinil on paediatric RAG list – currently AMBER for Sleepiness associated with narcolepsy</li> <li>• Metformin use in paediatrics</li> <li>• Amiodarone use in paediatrics</li> </ul>	Item 4i Item 4ii
<b>5) New Drugs from NTS and Formulary Subgroup Requiring a RAG Status</b> <ul style="list-style-type: none"> <li>a) Tiotropium for asthma</li> <li>b) Ultibro® (Indaceterol/glycopyrronium) inhaler</li> <li>c) Mysimba® (Naltrexone/bupropion)</li> </ul>	
<b>6) Progress with GMMM versions of SCPs</b> <ul style="list-style-type: none"> <li>a) Chapter 10 SCP Protocol Review – on hold</li> <li>b) Chapter 9 SCP Review - hydroxycarbamide</li> <li>c) Chapter 5 SCP Review - colistimethate for non-CF patients</li> </ul>	Item 6

<p><b>d) Chapter 4 SCP Review</b></p> <ul style="list-style-type: none"> <li>• ADHD drugs</li> <li>• Long acting injections</li> <li>• Lithium</li> <li>• Apomorphine</li> <li>• Modafinil</li> <li>• Riluzole</li> <li>• Ketamine (palliative care)</li> </ul> <p><b>e) Chapter 6 SCP Review</b></p> <ul style="list-style-type: none"> <li>• Growth hormone (adults)</li> <li>• Growth hormone(children)</li> </ul> <p><b>f) Cinacalcet for primary hyperparathyroidism SCP – awaiting GMMMG approval</b></p> <p><b>g) Ibandronate for breast cancer SCP – awaiting GMMMG approval</b></p> <p><b>h) Domperidone SCP for paediatric use</b></p> <p><b>i) Chapter 1 SCP review - sulfasalazine</b></p> <p><b>j) Chapter 8 SCP review</b></p>	
<p><b>7) 1<sup>st</sup> draft SCPs for IPS discussion</b></p> <ul style="list-style-type: none"> <li>• None this month</li> </ul>	
<p><b>8) Shared Care Protocols for Approval</b></p> <ul style="list-style-type: none"> <li>• Denosumab</li> </ul>	<p>Item 8a Item 8b</p>
<p><b>9) Shared Care Protocols on GMMMG Website to Archive as of May 2015</b></p>	<p>Item 9</p>
<p><b>10) Schedule for review of RAG list and associated shared care guidelines</b></p>	<p>Item 10</p>
<p><b>11) Forward work plan</b></p>	<p>Item 11</p>
<p><b>12) Inclusion of Grey/DNP List drugs on RAG list</b></p>	<p>Item 12</p>
<p><b>13) SCP Summary – Appendix to SCP template</b></p>	<p>Item 13a Item 13b Item 13c</p>
<p><b>14) Timings and Dates of Future IPS meeting</b></p>	<p>Item 14</p>
<p><b>15) Supply of dressings on discharge from secondary care</b></p>	
<p><b>16) Updates from other groups</b></p>	
<p>a) Formulary Subgroup (verbal)</p>	
<p>b) New Therapies Subgroup (verbal)</p>	
<p>c) GMMMG (verbal)</p>	
<p><b>17) AOB</b></p> <p><u>Olanzapine pamoate depot injection</u> Should it be Red not Amber due to 3hr observation period after each dose?</p> <p><u>Ondansetron in children</u> IPS asked to review RAG status and add to Paed RAG list</p>	
<p><b>Date of Next Meeting: 11<sup>th</sup> June 2015, 1pm-3pm Room 410, HMR CCG, Number One Riverside, Smith St, Rochdale OL16 1XU</b></p>	